Surgery, Gastroenterology and Oncology
Vol. 25, No. 5, Dec 2020
Clinical and Biological Characteristics of Breast Cancer in Women with Mammary Paget's Disease: A Retrospective Study of 36 cases
Mahmoud Al-Balas, Margherita Serra, Hamzeh Al-Balas, Donatella Santini, Mario Taffurelli
ORIGINAL PAPER, Dec 2020
Article DOI: 10.21614/sgo-25-5-236
Objective: Identification of clinical and biological characteristics of breast cancer in women with mammary Paget's disease (MPD).

Methods: We performed a retrospective analysis for 36 women with a primary diagnosis of mammary Paget's disease, patients were treated in Sant Orsola-Malpighi Breast Unit in Italy, between 2000 and 2016. Patients demographics, clinical data, radiologic and pathologic reports were extracted from electronic health records.

Result: 36 cases of patients with a diagnosis of MPD were involved. The mean age was 64.28 years (Range, 36-86 years). Only 14 patients (38.9%) were found to have an underlying breast mass. Invasive breast carcinoma was diagnosed in 23 patients (63.9%), 7 patients (19.4%) had ductal carcinoma in situ. All patients with associated breast mass were diagnosed with invasive breast carcinoma and they had a higher rate of axillary lymph node metastasis.
Most invasive breast carcinomas were HER2 positive (65.2%), estrogen and progesterone receptors negative (56.5% and 69.6%).

Conclusion: Mammary Paget's disease is a rare type of cancer that can be localized to nipple-areola complex or it can be associated with underlying breast carcinoma. Breast MRI has a higher sensitivity for identifying underlying breast pathology.
Once MPD is associated with an underlying mass, the likelihood of carcinoma is higher so a biopsy is recommended.
The expression of ER PR is lower in breast carcinomas with MPD, while they have higher HER2 neu expression. Unless multifocality or multicentricity is excluded, mastectomy is the recommended surgical treatment. Sentinel lymph node biopsy should be performed to evaluate the axilla when the invasive disease is identified or a mastectomy is planned.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3071


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Jun 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.